India May Drag U.S. To WTO In Case Of Unilateral IPR Action


"We are waiting for that report. The Indian government will not engage with private American firms," they added. Indian Ambassador to U.S. S Jaishankar had suggested that the government should engage with U.S. pharma firms on the matter. U.S. companies allege India's IPR regime is not compliant with international norms and discriminates against them.

Officials at the meeting, including Foreign Secretary Sujatha Singh, Commerce Secretary Rajeev Kher, DIPP Secretary Amitabh Kant and Health Secretary Lov Kumar Verma, appraised the Cabinet Secretary on all IPR-related issues between India and the U.S.

 According to sources, as part of trade sanctions, the U.S. may consider withdrawing benefits under the scheme of Generalised System of Preferences (GSP), which provides reduced tariffs for Indian goods entering the U.S. markets. "The withdrawal of GSP benefits may impact exports of MSME sector to the U.S. However, overall, the move would not impact Indian exporters much," they said.

Officials have said the demand is completely unfair as India's IPR regime is compliant with global laws, including the World Trade Organisation (WTO).

Read More:
Stable Govt Post-Elections To Help India Grow: Crisil
Economic Booster: Projects That Can Revamp India's Growth

Source: PTI